PMID- 35039449
OWN - NLM
STAT- MEDLINE
DCOM- 20230621
LR  - 20230621
IS  - 1472-4146 (Electronic)
IS  - 0021-9746 (Linking)
VI  - 76
IP  - 7
DP  - 2023 Jul
TI  - GATA3 positivity is associated with poor prognosis in patients with oesophageal 
      squamous cell carcinoma.
PG  - 474-479
LID - 10.1136/jclinpath-2021-208035 [doi]
AB  - AIMS: GATA-binding protein 3 (GATA3) is a zinc finger transcription factor with 
      diverse biological functions and is an excellent diagnostic marker for breast and 
      urothelial carcinoma. We aimed to study GATA3 expression in oesophageal squamous 
      cell carcinoma (SCC) and its significance with respect to histological features, 
      clinical parameters and overall survival. METHODS: We characterised GATA3 
      immunohistochemistry in 40 patients with oesophageal SCC. Electronic medical 
      records were reviewed for clinical and follow-up information, as well as patient 
      survival. RESULTS: Eleven (28%) oesophageal SCC were positive for GATA3. The 
      predominant stain patterns were patchy, with either mild or moderate intensities. 
      Patients with GATA3-positive tumours showed significantly shorter overall 
      survival than those with GATA3-negative tumours (p=0.023, Kaplan-Meier survival 
      analysis with log-rank test). In the multivariate Cox proportional hazards 
      regression model, GATA3 positivity was an independent adverse prognostic factor 
      for overall survival (p=0.019, HR 5.671). Surgery, definitive chemotherapy and/or 
      radiotherapy, and initial clinical stage were confirmed as independent prognostic 
      factors. CONCLUSION: To the best of our knowledge, this is the first study to 
      investigate the incidence of GATA3 positivity in oesophageal SCC and showed GATA3 
      positivity is associated with poor prognosis in oesophageal SCC.
CI  - (c) Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Chi, Zhikai
AU  - Chi Z
AUID- ORCID: 0000-0002-3601-3351
AD  - Department of Pathology, The University of Texas Southwestern Medical Center, 
      Dallas, Texas, USA zhikai.chi@utsouthwestern.edu.
FAU - Balani, Jyoti
AU  - Balani J
AD  - Department of Pathology, The University of Texas Southwestern Medical Center, 
      Dallas, Texas, USA.
FAU - Gopal, Purva
AU  - Gopal P
AD  - Department of Pathology, The University of Texas Southwestern Medical Center, 
      Dallas, Texas, USA.
FAU - Hammer, Suntrea
AU  - Hammer S
AD  - Department of Pathology, The University of Texas Southwestern Medical Center, 
      Dallas, Texas, USA.
FAU - Xu, Jing
AU  - Xu J
AD  - Department of Pathology, The University of Texas Southwestern Medical Center, 
      Dallas, Texas, USA.
FAU - Peng, Lan
AU  - Peng L
AD  - Department of Pathology, The University of Texas Southwestern Medical Center, 
      Dallas, Texas, USA.
LA  - eng
PT  - Journal Article
DEP - 20220117
PL  - England
TA  - J Clin Pathol
JT  - Journal of clinical pathology
JID - 0376601
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (GATA3 protein, human)
SB  - IM
MH  - Humans
MH  - *Esophageal Squamous Cell Carcinoma
MH  - *Carcinoma, Transitional Cell
MH  - *Urinary Bladder Neoplasms
MH  - *Esophageal Neoplasms/pathology
MH  - Prognosis
MH  - GATA3 Transcription Factor/metabolism
MH  - Biomarkers, Tumor/metabolism
OTO - NOTNLM
OT  - esophagus
OT  - immunohistochemistry
OT  - pathology
OT  - surgical
COIS- Competing interests: None declared.
EDAT- 2022/01/19 06:00
MHDA- 2023/06/21 06:42
CRDT- 2022/01/18 05:46
PHST- 2021/10/30 00:00 [received]
PHST- 2022/01/05 00:00 [accepted]
PHST- 2023/06/21 06:42 [medline]
PHST- 2022/01/19 06:00 [pubmed]
PHST- 2022/01/18 05:46 [entrez]
AID - jclinpath-2021-208035 [pii]
AID - 10.1136/jclinpath-2021-208035 [doi]
PST - ppublish
SO  - J Clin Pathol. 2023 Jul;76(7):474-479. doi: 10.1136/jclinpath-2021-208035. Epub 
      2022 Jan 17.